Navigation Links
CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
Date:10/11/2007

ith Regeneration Technologies, Inc.

Total tissue preservation services revenues were approximately $11.3 million in the third quarter of 2007, compared to $10.3 million in the third quarter of 2006, an increase of 10 percent. Total tissue preservation services revenues were approximately $36.0 million in the first nine months of 2007 compared to $29.8 million in the first nine months of 2006, an increase of 21 percent.

"We expect to post another profitable quarter for the third quarter of 2007. However, based on the results of the first nine months of 2007, we believe that we will be slightly below the lower end of our previous range of revenue guidance, which was $93 million," noted Steven G. Anderson, CryoLife president and chief executive officer.

"In addition, I'm pleased to announce that the FDA has completed a re- inspection of our facilities and no 483 Notice of Observations was issued. The re-inspection was related to our 510(k) submission for our CryoValve SG heart valve," Mr. Anderson added. "The re-inspection, coupled with our recent response to the FDA, completes the actions required of us at this point in connection with the FDA's review of our 510(k) application for our CryoValve SG heart valves. We remain optimistic that we will receive clearance for our CryoValve SG heart valve 510(k) application," Mr. Anderson concluded.

All statements relating to the Company's 2007 third quarter and first nine months revenues contained in this release are preliminary and unaudited, and may change based on the completion of customary quarter-end closing and review procedures.

Webcast and Conference Call Information

CryoLife's third quarter 2007 financial results will be released on Thursday, November 1, 2007. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, November 1, 2007, to discuss the results followed by a question and answer session hosted by Mr. Anderson.

To listen to the live t
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... -- Pomerantz LLP announces that a class action lawsuit has ... "Company")(NYSE: PBYI ) and certain of its officers.   ... Central District of California , and ... consisting of all persons or entities who purchased Puma ... inclusive (the "Class Period").  This class action seeks to ...
(Date:7/2/2015)... ELLYN, Ill. , July 2, 2015 ... Colton Eakins are gaining invaluable real-world experiences ... of Technology this summer. The students will ... Dr. Jeff Wereszczynski,s research group at IIT. The ... Dr. Tom Carter , Physics; Dr. Kathy ...
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become obsolete ... of sleep, launched its Indiegogo campaign on June 23. Sound sleepers and the sleep ... makes it effortless to use, while the integration of the Bluetooth speaker, alarm clock ...
(Date:7/1/2015)... and PARIS , July ... and Genective, key developer of biotech crops, today ... of new generations of insect control traits. ... to counter the realities of advancing insect resistance. ... AgBiome,s unique insect control technology with Genective,s capability ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4COD Students Participate in Prestigious Summer Internships 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2
... December 11 Olympus has further,cemented its position as ... signing an exclusive and immediate deal to distribute the ... the sole global,provider of ports for state-of-the-art laparoscopic operative ... Olympus is now the exclusive,distributor for the full range ...
... PPHM ) today announced that Thomas A. Waltz, M.D., ... Dr. Waltz had been a director of Peregrine since 2004 ... death, Dr. Waltz served on Peregrine,s Audit Committee, Compensation Committee and ... "The sudden loss of our business colleague and friend Tom Waltz ...
... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) ... statistical endpoint in its multi-centre Phase 2 clinical ... in patients with various sarcomas that have metastasized ... of patients on study with significant, durable, clinically ...
Cached Biology Technology:Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 4
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
(Date:6/23/2015)... RALEIGH, N.C. , June 23, 2015 /PRNewswire/ ... technology, today announced the results of a recent ... unmatched accuracy on the wrist during activity. In ... biometric technology was compared along with the Apple ... for accurately measuring heart rate during activity. The ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... ) can today be found all over Central Europe, Asia, ... in the Iberian Peninsula at the end of the Early ... an international research study, with Spanish participation, which has discovered ... of fossils found in the Cueva Victoria deposit in Cartagena ...
... of newly installed, hands-free faucets at The Johns Hopkins Hospital, ... hands and dispense preset amounts of water, shows they were ... common and hazardous bacteria in hospitals compared to old-style fixtures ... "Newer is not necessarily better when it comes to ...
... (SACRAMENTO, Calif.) UC Davis cancer researchers have found ... for surveillance with regular CT scans over lymph node ... findings, published online last week in the journal Cancer, ... cancers with surveillance when discussing treatment options with their ...
Cached Biology News:Green toad inhabited Iberian Peninsula 1 million years ago 2Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 2Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 3Latest hands-free electronic water faucets found to be hindrance, not help, in infection control 4Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
LabFax: Immunochemistry...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
Biology Products: